High levels of engagement between healthcare providers and people living with HIV are associated with better health outcomes

London, 4 July 2020 – ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented four abstracts at the Virtual, 23rd International AIDS Conference (AIDS 2020), providing insights into the unmet needs of people living with HIV (PLHIV). Positive Perspectives, Wave 2 study (Positive Perspectives 2) results highlight the importance of a holistic approach involving people living with HIV in open dialogue and joint decision-making with their healthcare providers (HCPs), particularly as people living with HIV plan for healthy ageing. These patient-reported outcomes data demonstrate that empowered people living with HIV who work with their HCPs on this collaborative approach were more likely to report viral suppression and, importantly, improvements in aspects of quality of life.

Study results highlighted:

  • High HCP-PLHIV engagement was associated with significantly better reported health outcomes,1 and improving the quality of this communication may better support improvements in aspects of quality of life, beyond viral suppression.1
    • Of those people living with HIV in the study with high engagement in their care, 70% (456/813) reported optimal overall health, compared to 46% (334/756) reporting optimal overall health among those with low engagement in their care.1
    • 88% (716/813) of those with high engagement reported treatment satisfaction compared to 47% (340/756) with low engagement.1
    • 65% (1,556/2,389) of people living with HIV in the study agreed that they would like to be more involved in treatment decisions about their HIV care, yet 77% (1,847/2,389) reported ≥one issue they felt uncomfortable discussing with their HCPs.1
  • Those in the study who reported being informed of U=U by their HCPs (66%, 1,588/2,389) reported more favourable health outcomes than those reporting they were not informed by their HCPs.2
  • Almost one quarter (23%, 161/699) of people living with HIV aged ≥50 years in the study reported suboptimal physical, mental, sexual and overall health.3
    • Over three quarters (76%, 480/632) of treatment-experienced people living with HIV aged ≥50 years in the study reported that ensuring minimal side effects is the treatment topic most important to them.4
    • In people living with HIV aged ≥50 years in the study, communication issues can hinder optimisation of care with 53% (335/632) of treatment-experienced and 84% (56/67) of newly-diagnosedindividuals reporting barriers to raising concerns with HCPs, including medicine-related concerns.4

Dr. Benjamin Young, Head, Global Medical Directors of ViiV Healthcare, said: “As the care of people living with HIV has progressed, the focus has moved away from simply surviving, to living and wellness with HIV, with improved quality of life as the desired goal.  As people living with HIV grow older, their life priorities and treatment needs may evolve; consequently, it is important that they work in close partnership with their healthcare providers to identify and plan for these changes. The Positive Perspectives 2 study represents the voices of people living with HIV from 25 countries and shows us ways that a collaborative and holistic approach to HIV care can improve health outcomes.”

One of the largest, global, HIV patient-reported outcomes studies to date, Positive Perspectives 2 includes input from a diverse group of 2,389 people living with HIV, aged 18 – 84 from 25 countries; the research was developed in collaboration with an international, multi-disciplinary Advisory Committee including PLHIV, HCPs and representatives from HIV support groups. The study investigates how people living with HIV rate their own health, how living with HIV impacts their lives and affects their outlook for the future, examines their interactions and relationships with HCPs and their experiences with antiretroviral therapy. The insights gained from the study can help address the unmet needs and challenges faced by people living with HIV and contribute towards improving quality of life.

Erika Castellanos, Director of Programs, Global Action for Trans Equality (GATE) and Positive Perspectives 2 Advisory Committee Member, said: “Results from the Positive Perspectives 2 study provide insights into the challenges we face as people living with HIV. While great advances have been made in the treatment of HIV, these results show that those of us living with HIV still need support to empower us to confidently advocate for ourselves across all aspects of our care.  HIV makes us more vulnerable to other health conditions, so it is crucial that we feel licensed to play active roles in our HIV care and regularly discuss changing treatment needs with our HCPs.”

To read more about the results from the Positive Perspectives 2 study, please visit Positive Perspectives 2 to review the global study report, including additional data on polypharmacy and HIV in women.

Notes to Editors

Open and active dialogue: results in more detail
Results from Positive Perspectives 2 showed that people living with HIV in the study who reported being informed about U=U by their HCPs (66%, 1,588/2,389) were significantly more likely than those who reported not being informed by their HCPs to indicate:

  • Treatment satisfaction (76%, 1,201/1,588 vs. 57%, 456/801)2
  • Optimal adherence (80%, 1,266/1,588 vs. 68%, 548/801)2
  • Self-reported viral suppression (77%, 1,220/1588 vs. 69%, 551/801)2
  • Optimal overall (61%, 967/1,588 vs. 51%, 410/801), mental (62%, 993/1,588 vs. 48%, 384/801), and sexual health (51%, 815/1,588 vs. 43%, 347/801)2

Ageing well with HIV: results in more detail
It is currently estimated that there are almost nine million people living with HIV aged ≥50 years worldwide.5 Longer life increases the likelihood of comorbidities and polypharmacy, which in turn can have impacts on various health outcomes.3 Positive Perspectives 2 demonstrates this with 44% (308/699) of people living with HIV aged ≥50 years reporting suboptimal physical health, 38% (267/699) suboptimal mental health, 61% (423/699) suboptimal sexual health and 46% (322/699) suboptimal overall health.3 Almost one quarter (23%, 161/699) reported suboptimal health on all four domains and those most at risk for this category were those reporting two or more comorbidities, poor adherence, treatment dissatisfaction or gastrointestinal side effects from antiretroviral therapy.3

About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline and commitment, please visit

About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and any impacts of the COVID-19 pandemic.

ViiV Healthcare media enquiries:


Patricia O’Connor (Global)

Audrey Abernathy (US)

+44 (0) 7469 375019 (London)

+1 919 605 4521 (Research Triangle Park)

GSK UK media enquiries:

GSK US media enquiries:

Tim Foley

Kathleen Quinn

+44 (0) 20 8047 5502 (London)

+1 202 603 5003 (Washington DC)


Analyst / Investor enquiries:


Sarah Elton-Farr

Danielle Smith

James Dodwell

Jeff McLaughlin

Frannie DeFranco

+44 (0) 20 8047 5194 (London)

+44 (0) 20 8047 0932 (London)

+44 (0) 20 8047 2406 (London)

+1 215 751 7002 (Philadelphia)

+1 215 751 4855 (Philadelphia)


  1. Okoli C, Brough G, Allan B, Castellanos E, Young B, Eremin A, Corbelli GM, Mc Britton M, Muchenje M, Van de Velde N, de los Rios. Putting the heart back into HAART: greater HCP-patient engagement is associated with better health outcomes among persons living with HIV (PLHIV) on treatment; Poster PED 0808 Presented at the 23rd International AIDS Conference, July 6 – 10, 2020.
  2. Okoli C, Richman B, Allan B, Brough G, Castellanos E, Young B, Eremi A, Corbelli GM, McBritton M, Hardy D, M Muchenje, Van de Velde N, de los Rios P. A tale of two ‘U’s and their use by healthcare providers: a cross country analysis of information sharing about undetectable = untransmittable (U=U); Poster PED 0773 Presented at the 23rd International AIDS Conference, July 6 – 10, 2020.
  3. Short D, Spinelli F, Okoli C, de los Rios P. Clinical and sociodemographic characteristics associated with poor self-rated health across multiple domains among older adults living with HIV; Oral OAD 0903 Presented at the 23rd International AIDS Conference, July 6 – 10, 2020.
  4. Short D, Spinelli F, Okoli C, de los Rios P. Understanding the changing treatment concerns of older people living with HIV and difficulties with patient-provider communication; Poster PED 0787 Presented at the 23rd International AIDS Conference, July 6 – 10, 2020.
  5. UNAIDS. Get on the fast-track, the life-cycle approach to HIV 2016. Accessed June 2020